Memorandum by the Public Health Genetics
Network Executive Group
SUMMARY
The Executive of the Public Health Genetics
Network supports:
(a) the establishment of genetic databases
provided appropriate safeguards are in place;
(b) the protection of all personally identifiable
health data (including genetic data however defined) by the full
force of the law;
(c) the need to distinguish the release of
personally identifiable data (which must be subject to stringent
safeguards of consent and confidentiality) from the release of
anonymised, coded or encrypted data for epidemiological purposes
or for research activities (which may legitimately be carried
out provided always that the privacy of the individual is protected
and that individuals using health services, or involved in research
programmes, have been made aware that their anonymised or coded
data might be used for these purposes, and have given general
consent for this purpose);
(d) the use of primary legislation to safeguard
genetic and epidemiological databases from its use for forensic
or any other reasons unrelated to its prime purpose.
SUBMISSION
The Executive Group of the Public Health Genetics
Network (PHGN) is grateful for the opportunity to submit its views
to the House of Lords inquiry into Genetic Databases. The Network
was established in March 1998 by the Public Health Genetics Unit
in consultation with Regional Directors of Public Health. Its
purpose is to provide a forum to discuss issues of public health
importance arising out of genetic science. Its members are public
health physicians representing the health regions of England and
the devolved territories of Scotland, Wales and Northern Ireland
together with representatives from the Department of Health, the
British Society of Human Genetics, the MRC and the Wellcome Trust.
1. We support the view that genetic science
will result in enormous benefits to health and health care. We
believe that it is in the public's interest to support the establishment
of genetic databases, and that their use in correlating gene sequences
with disease will lead to significant benefits for the UK population.
The pace at which this knowledge will impact on clinical and public
health interventions may be debated but there is a consensus that
such gains will eventually materialise.
2. We believe that issues of consent, confidentiality,
security and other ethical matters are integral to this debate.
The development of these databases must take full account of these
issues. The protection of the privacy of the individual citizen
is paramount.
3. We support without reservation the view
that all personally identifiable health data (including genetic
data however defined) must be protected by the full force of the
law. We endorse the view that consent is essential for the collection
of such data whether for clinical purposes or for the purpose
of research. We also believe that considerations of confidentiality
demand that the release of personally identifiable data to third
parties must require explicit consent unless subject to the set
of exceptions laid out in GMC guidance or in the Data Protection
Act 1998. These principles are fundamental and should not be compromised.
4. The implication of these views is that
consent, explicit or implied, is required whenever health information
or tissue are given by individuals to health professionals in
the course of a clinical consultation or for the purposes of research.
It will be rightly and properly assumed by individuals that data
and the tissue given in a clinical context will be used only for
that purpose and for their benefit. If the health professional
seeks to use personally identifiable health data for other purposes
explicit consent will need to be sought. In similar vein, consent
for a research project should be deemed to be given only for that
project; further consent will be required if personally identifiable
health data is needed for another research purpose. These principles
are already well set out in official guidance from a variety of
sources.
5. These stringent criteria, which refer
to the use of personally identifiable data and tissue, must be
applied without exception if individual privacy is to be protected.
By contrast we distinguish a situation where personal health data
or tissue are released to third parties in a form that does not
allow the individual to be personally identified. We suggest that,
in these circumstances, consent for the release of the data or
tissue is unnecessary, and that neither ethical nor legal considerations
demand it. Personal health data or information from tissue specimen
released anonymously, or in a coded or encrypted form, to a
bona fide third party for bona fide purposes will not
cause any individual to suffer any form of detriment as a consequence
of that release. These considerations do not apply to persons
who are not bona fide, or to bona fide persons for
non bona fide purposes.
6. We are aware of the argument that, by
releasing anonymised data, we breach the individual's autonomy
and dignity. We suggest that there are two compelling arguments
that override this objection. First, we believe that anonymous
disclosure is not a breach of confidentiality since by definition
there will be no individual whose confidentiality can be said
to have been breached. By analogy any allegation that an individual's
autonomy and dignity might be breached is in our view theoretical
and de minimis. Second, even if autonomy and dignity were
in some way breached, we believe that they would have to be balanced
against public interest considerations. Although in most cases
the arguments for individual autonomy and dignity will prevail,
where there is a large and significant public interest in having
data released for epidemiological purposes or for research and
the damage to individual autonomy is theoretical and de minimis,
we suggest that the public interest should prevail.
7. We draw the Committee's attention to
the judgement of Lord Justice Simon Brown in the Court of Appeal
in the Source Informatics case. We consider that judgement
to be of the greatest relevance to the issue of genetic databases.
The essence of the judgement was that there could be no breach
of confidentiality in the release of anonymised data by a health
professional to a third party, provided that the release was in
good faith and did not breach the conscience of the health professional.
It was not necessary as a matter of law to consider whether the
release could be justified by reference to the public interest.
There could be no breach of confidentiality because the matter
which confidentiality was designed to protectthe privacy
of the individualwas not at issue.
8. We believe that the release of anonymised
or coded data to epidemiological, genetic or administrative databases
is necessary and entirely justifiable in the interests of public
health. Cancer registration is a case in point. We believe that
the application of burdensome ethical barriers (applicable to
situations where the release of data can be traced back to individuals)
to these circumstances (where one is unable to make the connection
with identifiable individuals) will be detrimental and serve no
useful or ethical purpose. We believe that it should not be necessary
to require explicit consent for each individual episode or release
of data, provided always that the privacy of the individual is
protected and that individuals using health services (or involved
in research programmes) have been made aware that their anonymised
or coded data might be used for epidemiological and genetic research,
and have through an explicit or implied process given general
consent for this purpose.
9. We are aware that the privacy of individuals
may not be totally protected by coded or encrypted data (as distinct
from anonymised data). We share these concerns and urge that legislation
be enacted to prevent the use of epidemiological databases, with
or without a genetic component, for forensic or any other purposes
unrelated to epidemiological documentation and research.
Dr Ron Zimmern MA, FRCP, FFPHM
Chairman, Public Health Genetics Network
1 October 2000
|